Study Uncovers Triple Immunotherapy Combination as Potential Treatment for Pancreatic Cancer | Rutgers Cancer Institute
The novel triple immunotherapy combination targeting checkpoints on both T cells and myeloid suppressor cells dramatically improved anti‑tumor responses in preclinical models of pancreatic ductal adenocarcinoma.
PDAC is one of the leading causes of cancer death in the United States and is considered to be 'non‑immunogenic,' which means it is unresponsive to commonly used anti‑PD‑1 and anti‑CTLA‑4 immune checkpoint therapy. This is partly due to the immunosuppressive conditions in the tumor microenvironment, but the mechanisms behind this resistance are not well understood.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.